Baseline Characteristics of Patients and Pathologic Response After Neoadjuvant Therapy
| Number or mean ± SD | |||
| Characteristic | Chemotherapy | Endocrine therapy | P |
| Age (y) | 58.4 (5.4) | 60.9 (5.3) | 0.24 |
| Histology | 0.48 | ||
| Invasive ductal carcinoma | 13 | 11 | |
| Invasive lobular carcinoma | 0 | 2 | |
| Histologic grade | 0.22 | ||
| 2 | 13 | 10 | |
| 3 | 0 | 3 | |
| ER (Allred score) | 0.83 | ||
| 6 | 1 | 1 | |
| 7 | 1 | 2 | |
| 8 | 11 | 10 | |
| Progesterone receptor | 0.42 | ||
| Positive | 9 | 7 | |
| Negative | 4 | 6 | |
| HER2 | 0.30 | ||
| Positive | 1 | 1 | |
| Equivocal | 3 | 1 | |
| Negative | 9 | 11 | |
| 18F-FES PET/CT | 0.48 | ||
| Visual analysis | |||
| Negative | 2 | 0 | |
| Positive | 11 | 13 | |
| SUVmax | 6.6 ± 3.9 | 12.0 ± 9.2 | 0.06 |
| Pathologic response (Miller–Payne grade)* | 0.12 | ||
| 2 | 4 | 9 | |
| 3 | 6 | 4 | |
| 4 | 0 | 0 | |
| 5 | 2 | 0 | |
| % reduction in tumor cellularity* | 50.8 ± 35.0 | 22.7 ± 17.4 | 0.02 |
↵* Pathologic response after NC was analyzed in 12 patients.